Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee. "Typically, we see 3...
Source LinkBiotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee. "Typically, we see 3...
Source Link
Comments